Floatz logo

Kyv-101

Stiff-Person Syndrome

Kyverna TherapeuticsCell therapyActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Stiff-Person Syndrome cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Fred Hutchinson Cancer Center
Phase 2CCC
CARMUSTINE
Fred Hutchinson Cancer Center
Phase 2CCC
Anti-Thymoglobulin, Rabbit
Fred Hutchinson Cancer Center
Phase 2CCC
Evomela
Fred Hutchinson Cancer Center
Phase 2CCC
ETOPOSIDE
Fred Hutchinson Cancer Center
Phase 2CCC
Cytosin-Arabinosid
Fred Hutchinson Cancer Center
Phase 2CCC

Same molecule, other indications

Kyv-101 is also rated in:

primary progressive multiple sclerosisDormant
B
Indicative ·
60 / 100
View asset →
secondary progressive multiple sclerosisDormant
B
Indicative ·
60 / 100
View asset →
multiple sclerosisDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →